Log In
Print this Print this

MVA-MUC1-IL2 (TG4010)

  Manage Alerts
Collapse Summary General Information
Company Transgene S.A.
DescriptionRecombinant modified vaccinia Ankara (MVA) virus vector that expresses the mucin 1 (MUC1; CD227) tumor-associated antigen combined with interleukin-2 (IL-2)
Molecular Target Mucin 1 (MUC1) (CD227) ; Interleukin-2 (IL-2)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II/III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsSecond-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC); Treat advanced or metastatic MUC1-positive non-small cell lung cancer (NSCLC) stage IIIB or IV; Treat non-small cell lung cancer (NSCLC)
Regulatory Designation U.S. - Fast Track (Treat non-small cell lung cancer (NSCLC))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today